Bliss GVS Pharma Unit Obtains Authorization for Mesalazine Suppositories
A Bliss GVS Pharma unit obtained marketing authorization from MHRA for Mesalazine 1g suppositories.
Related stories
Burjeel Holdings Q3’26 Finance Costs Rise 66.5% to AED 62 Million
M impact | EQUITY | Nov 04, 2026, 01:23 PM UTC
Norwegian Air shares rise 5.2%, on track for best day since June
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Shringar House of Mangalsutra Reports Q2 Revenue of INR 8,186.6 Million
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Crédit Mutuel Arkéa Contains Cyberattack; Operations Gradually Resume
The bank said clients’ assets were not affected.
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Crédit Mutuel Arkéa Contains Cyberattack as Operations Gradually Resume
The bank said clients’ assets have not been affected.
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC
Crédit Mutuel Arkéa Says It Was Targeted in Cyberattack
M impact | EQUITY | Nov 04, 2026, 01:22 PM UTC